Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 225 Franklin Street, Suite 2100 BOSTON MA 02110 |
Tel: | 1-617-8182985 |
Website: | https://ateapharma.com |
IR: | See website |
Key People | ||
Jean-Pierre Sommadossi Chairman of the Board, President, Chief Executive Officer, Founder | Andrea J. Corcoran Chief Financial Officer, Executive Vice President - Legal , Secretary | Wayne Foster Executive Vice President, Chief Accounting Officer |
Janet Hammond Chief Development Officer | Maria Arantxa Horga Chief Medical Officer | John Vavricka Chief Commercial Officer |
Business Overview |
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients. |
Financial Overview |
For the fiscal year ended 31 December 2023, Atea Pharmaceuticals Inc revenues was not reported. Net loss increased 17% to $136M. Higher net loss reflects COVID-19 external costs increase from $19.5M to $44.2M (expense), Research and development increase of 17% to $47.4M (expense), Stock-based Compensation Expense increase of 8% to $26.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.39 to -$1.63. |